Interactive Clinical Trial Research
Understanding Our Data
Our research provides transparent information and analyses of drug discovery and development.
CRIB analyzes FDA-approved medicines and other FDA-approved biomedical products, including vaccines and biologicals. CRIB investigators are also deepening our knowledge of the scientific, medical and commercial evolution of FDA-approved products.
CDEK Year In Review
Our yearly review papers that inspect the constantly changing landscape of the Pharmacetuical Industry.
A broad look at APIs, Organizations, and Indications discoveries in Clinical
Trials each year. We record new approvals and trends in disease areas and regulatory mechanisms.
An analysis of FDA-approved drugs: natural products and their derivatives
E Patridge, P Gareiss, MS Kinch, D Hoyer Drug discovery today 21 (2), 204-207An assessment of all FDA-approved NMEs reveals that natural products and their derivatives represent over one-third of all NMEs. Nearly one-half of these are derived from mammals, one-quarter from microbes and one-quarter from plants. Since the 1930s, the total fraction of natural products has diminished, whereas semisynthetic and synthetic natural product derivatives have increased.
How many FDA Approved drugs have been withdrawn and why are aspiring drugs abandoned?
A review of the process to withdraw or abandon medicines.
WANTED DEAD OR ALIVE: New Thinking to Incentivize Drug Development
Despite advancements our continued ability to develop new medicines is fundamentally in doubt.